PH12012501371A1 - Methods and compositions for applying moxifloxacin to the ear - Google Patents

Methods and compositions for applying moxifloxacin to the ear

Info

Publication number
PH12012501371A1
PH12012501371A1 PH1/2012/501371A PH12012501371A PH12012501371A1 PH 12012501371 A1 PH12012501371 A1 PH 12012501371A1 PH 12012501371 A PH12012501371 A PH 12012501371A PH 12012501371 A1 PH12012501371 A1 PH 12012501371A1
Authority
PH
Philippines
Prior art keywords
moxifloxacin
ear
tympanic membrane
methods
compositions
Prior art date
Application number
PH1/2012/501371A
Other languages
English (en)
Inventor
Belinda W Y Cheung
Ronald J Sawchuk
G Michael Wall
Original Assignee
Novartis Ag
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44306169&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12012501371(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Univ Minnesota filed Critical Novartis Ag
Publication of PH12012501371A1 publication Critical patent/PH12012501371A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PH1/2012/501371A 2010-01-07 2011-01-07 Methods and compositions for applying moxifloxacin to the ear PH12012501371A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29301910P 2010-01-07 2010-01-07
PCT/US2011/020531 WO2011085209A2 (en) 2010-01-07 2011-01-07 Methods and compositions for applying moxifloxacin to the ear

Publications (1)

Publication Number Publication Date
PH12012501371A1 true PH12012501371A1 (en) 2012-10-22

Family

ID=44306169

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2012/501371A PH12012501371A1 (en) 2010-01-07 2011-01-07 Methods and compositions for applying moxifloxacin to the ear

Country Status (24)

Country Link
US (1) US20120289541A1 (enExample)
EP (2) EP2521547B1 (enExample)
JP (3) JP2013516485A (enExample)
KR (2) KR101835895B1 (enExample)
CN (2) CN102791270A (enExample)
AU (1) AU2011204275B2 (enExample)
BR (1) BR112012016809A2 (enExample)
CA (1) CA2786525A1 (enExample)
CL (1) CL2012001835A1 (enExample)
CY (1) CY1119493T1 (enExample)
DK (1) DK2521547T3 (enExample)
ES (1) ES2644826T3 (enExample)
HR (1) HRP20171592T1 (enExample)
HU (1) HUE035586T2 (enExample)
LT (1) LT2521547T (enExample)
MX (1) MX337419B (enExample)
NO (1) NO2521547T3 (enExample)
PH (1) PH12012501371A1 (enExample)
PL (1) PL2521547T3 (enExample)
PT (1) PT2521547T (enExample)
RU (2) RU2016101214A (enExample)
SI (1) SI2521547T1 (enExample)
WO (1) WO2011085209A2 (enExample)
ZA (1) ZA201205965B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220431B2 (en) * 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
AU2013284453A1 (en) * 2012-06-28 2015-01-22 The Administrators Of The Tulane Educational Fund Selectively polymerizable compositions and methods of use in Vivo
CN103869033B (zh) * 2012-12-14 2016-10-05 南京长澳医药科技有限公司 一种液相色谱法分离测定盐酸莫西沙星及其杂质的方法
JP6255134B1 (ja) * 2016-11-02 2017-12-27 ヴェローチェ・バイオファーマ・エルエルシー 耳炎の治療のための組成物および方法
CN111601588A (zh) * 2017-12-08 2020-08-28 约翰霍普金斯大学 用于增强粘膜表面处活性剂运输的低渗水凝胶配制物
CN108593696B (zh) * 2018-04-26 2020-11-03 南京明捷生物医药检测有限公司 一种利用定量核磁测定多肽中三氟乙酸残留的方法
CN117045593B (zh) * 2023-09-19 2024-05-28 上海市第六人民医院 一种用于慢性中耳炎治疗的抗菌温敏水凝胶及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6740664B2 (en) * 1998-09-30 2004-05-25 Alcon, Inc. Methods for treating otic and ophthalmic infections
AR020661A1 (es) * 1998-09-30 2002-05-22 Alcon Lab Inc Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
JP3450805B2 (ja) * 2000-08-08 2003-09-29 わかもと製薬株式会社 水性医薬組成物
US7220431B2 (en) * 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
WO2006065301A2 (en) * 2004-12-10 2006-06-22 Alcon, Inc. Compositions for treatment of ear infections
WO2009142719A2 (en) * 2008-05-19 2009-11-26 Massachusetts Institute Of Technology Tympanic membrane permeating ear drops and uses thereof

Also Published As

Publication number Publication date
CA2786525A1 (en) 2011-07-14
EP2521547A2 (en) 2012-11-14
CY1119493T1 (el) 2018-03-07
MX337419B (es) 2016-03-03
RU2576029C2 (ru) 2016-02-27
EP2521547B1 (en) 2017-08-16
LT2521547T (lt) 2017-12-11
MX2012007928A (es) 2012-11-22
RU2016101214A (ru) 2018-11-21
HUE035586T2 (en) 2018-05-28
WO2011085209A2 (en) 2011-07-14
JP6267246B2 (ja) 2018-01-24
EP2521547A4 (en) 2014-03-26
ES2644826T3 (es) 2017-11-30
WO2011085209A3 (en) 2011-11-17
PT2521547T (pt) 2017-11-17
EP3305280A1 (en) 2018-04-11
JP2018076352A (ja) 2018-05-17
RU2012133568A (ru) 2014-02-20
HRP20171592T1 (hr) 2018-02-09
ZA201205965B (en) 2014-01-29
AU2011204275A1 (en) 2012-08-23
KR20180027611A (ko) 2018-03-14
CN102791270A (zh) 2012-11-21
CL2012001835A1 (es) 2013-03-22
AU2011204275B2 (en) 2015-04-02
KR20120114344A (ko) 2012-10-16
BR112012016809A2 (pt) 2017-09-26
NO2521547T3 (enExample) 2018-01-13
US20120289541A1 (en) 2012-11-15
DK2521547T3 (da) 2017-11-20
PL2521547T3 (pl) 2018-01-31
JP2013516485A (ja) 2013-05-13
SI2521547T1 (en) 2018-02-28
CN106309356A (zh) 2017-01-11
JP2016155808A (ja) 2016-09-01
KR101835895B1 (ko) 2018-03-07

Similar Documents

Publication Publication Date Title
PH12012501371A1 (en) Methods and compositions for applying moxifloxacin to the ear
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
MX2010014041A (es) Una forma cristalina de posaconazol.
PH12015501737B1 (en) Androgen receptor modulators and uses thereof
WO2011013003A3 (en) Intranasal granisetron and nasal applicator
PH12013500481A1 (en) Estrogen receptor modulators and uses thereof
PH12012502419A1 (en) Estrogen receptor modulators and uses thereof
PH12014501351B1 (en) Fluorinated estrogen receptor modulators and uses thereof
WO2010002956A3 (en) Heterocyclic derivatives as modulators of ion channels
JO3078B1 (ar) مورفولينوثيازولات بصفتها منظمات الوستيرية نوع الفا 7 موجبة
MX2012000396A (es) Metodos y composiciones para uso en tartamientos celulares.
EP2044108A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND TREATMENT OF ISCHEMIC SUDIDS AND METHOD FOR THEIR ADMINISTRATION
MX2010004953A (es) Formulaciones de solucion oftalmica u otica topicas que contienen clorihidrato de moxifloxacina y fosfato de dexametasona.
WO2011141685A3 (fr) Compositions nasales a visee systemique a base de cocoyl proline ou d'au moins un de ses constituants
MX2013004693A (es) Composiciones de aripiprazol y metodos para su suministro transdermico.
ZA201003352B (en) Heterocyclic derivatives as modulators of ion channels
EP2583969A4 (en) NEW RHODANINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS WITH THE RHODANIN DERIVATIVES AS ACTIVE AGENTS
NZ630241A (en) Laquinimod formulations without alkalizing agent
MX345656B (es) (piridin-4-il)bencilamidas como moduladores alostericos de nachr alfa 7.
ZA201203028B (en) Compositions, use and method for the use of surface active proteins in topical drug delivery across keratin
MY171526A (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
WO2014169920A3 (en) Use of a microbial composition for the degradation of keratinaceous materials
MX2016003230A (es) Complejo lubricante para la boca.
GB2510314A (en) Antiseptic chewing gum
EP3823674A4 (en) CONJUGATES FOR DELIVERING AN ANTI-CANCER AGENT TO NERVE CELLS, METHODS OF USE AND METHODS OF PRODUCTION THEREOF